Pharmaceutical compositions comprising poh derivatives

Abstract

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH) having the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is administered before, during, or after radiation. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         4 . A pharmaceutical composition comprising hexadecanoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (palmitoyl ester of POH) having the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition is administered before, during, or after radiation. 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         7 . A method for treating a disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH). 
     
     
         8 . The method of  claim 7 , wherein the pharmaceutical composition is administered before, during or after radiation treatment. 
     
     
         9 . The method of  claim 7 , further comprising administering to the mammal a chemotherapeutic agent. 
     
     
         10 . The method of  claim 7 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         11 . The method of  claim 7 , wherein the disease is cancer. 
     
     
         12 . The method of  claim 11 , wherein the cancer is selected from the group consisting of: lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system; and combinations thereof. 
     
     
         13 . A method for treating a disease in a mammal, comprising the step of delivering to the mammal the pharmaceutical composition of  claim 4 . 
     
     
         14 . The method of  claim 13 , further comprising delivering to the mammal a chemotherapeutic agent. 
     
     
         15 . The method of  claim 13 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         16 . The method of  claim 13 , wherein the disease is cancer. 
     
     
         17 . The method of  claim 16 , wherein the cancer is selected from the group consisting of: lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system; and combinations thereof.